| News

Vaximm is using AI to develop cancer vaccines

12.11.2019

Basel-based biotech company Vaximm has agreed a collaboration with IT company NEC. Vaximm wants to develop personalized cancer vaccines using NEC’s artificial intelligence (AI)-based prediction system.

Vaccine (Img: PhotoLizM/Pixabay)

According to a press release by Vaximm, Vaximm and NEC have agreed to cooperate on a non-exclusive basis. As part of the collaboration, NEC will make an equity investment in Vaximm. In addition, the Tokyo-based IT company will provide funding for a Phase I clinical trial for personalized neoantigen cancer vaccines.

The two partners want to develop the vaccines through the agreed collaboration. Vaximm will provide its experience in developing oral T-cell immunotherapies for patients, while NEC has developed a neoantigen prediction system based on state-of-the-art artificial intelligence (AI) technology, which is to be utilized in the development of cancer vaccines. Vaximm will manage the clinical trial scheduled for the coming year. NEC has secured the development and commercialization rights to the program worldwide, except for China and other Asian territories, which also apply to Japan.

Heinz Lubenau, PhD, Chief Operating Officer and Co-Founder of Vaximm, said: “NEC’s novel AI technology will enable not only the identification but also the prioritization of neoantigens from each patient. Once the list of neoantigens is available, we will be able to apply our technology to quickly produce a personalized vaccine. “

Vaximm is headquartered in the Technology Park, Basel. The location will be pleased to hear another success story from one of its companies based there. This means an extension of the cooperation between NBE Therapeutics and the Czech biotech company Sotio. NBE Therapeutics specializes in developing antibody drug conjugate products for cancer treatment. The two companies want to work together to develop next-generation antibody drug conjugates. Sotio has now exercised the option for developing a second drug candidate. NBE Therapeutics will also be able to use its in-house platform for this, while Sotio has the corresponding commercial rights. The exercise of the option by Sotio will give NBE the right to receive certain payments.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Basel Area – exactly the right chemistry for South Korean pharma companies
Basel Area Business & Innovation, Innovation, Invest

Basel Area – exactly the right chemistry for South Korean pharma companies

KPBMA and Basel Area Business & Innovation establish tailored collaboration to support Korean biopharmaceutical companies to enter the European market

Read More
Basel Area supporting three digital health startups
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Basel Area supporting three digital health startups

Basel Area Business & Innovation will be offering intensive support to the three winners of its DayOne Digital Health Accelerator...

Read More
Gray establishes presence in Basel
Basel Area Business & Innovation, Innovation, Invest

Gray establishes presence in Basel

The North American fully integrated specialty service provider Gray has established a subsidiary in Basel. The key factors in favor...

Read More
Artificial Intelligence able to identify potentially life-saving antibiotics
Basel Area Business & Innovation, Innovation, Invest

Artificial Intelligence able to identify potentially life-saving antibiotics

A computer algorithm has identified antibiotics that that are still effective against infections in which multi-resistant germs are present. University...

Read More
Investors give Anaveon 110 million Swiss francs
Basel Area Business & Innovation, Innovation, Invest

Investors give Anaveon 110 million Swiss francs

Anaveon has received investment commitments amounting to 110 million Swiss francs in a Serie B funding round. The Basel-based biopharmaceutical...

Read More
Basel alliance seeks to combat antibiotic resistance
Basel Area Business & Innovation, Innovation, Invest

Basel alliance seeks to combat antibiotic resistance

The Spearhead alliance has been founded in Basel with the aim of combating the silent pandemic of antimicrobial resistance. By...

Read More
Kinarus and Noorik awarded federal grants
Basel Area Business & Innovation, Innovation, Invest

Kinarus and Noorik awarded federal grants

The Basel-based biopharmaceutical companies Kinarus and Noorik have been awarded federal grants for their clinical trials investigating drug candidates to...

Read More
Alloy acquires deepCDR and will expand Basel site
Basel Area Business & Innovation, Innovation, Invest

Alloy acquires deepCDR and will expand Basel site

Alloy Therapeutics, a biotechnology firm from Boston in the USA, has acquired the Basel-based startup deepCDR Biologics. Alloy labs and...

Read More
Basel Healthtech fund successfully closed
Basel Area Business & Innovation, Innovation, Invest

Basel Healthtech fund successfully closed

The venture capital firm MTIP has announced the successful closing of its FUND II. It is one of the first...

Read More
Roche tests able to detect Omicron
Basel Area Business & Innovation, Innovation, Invest

Roche tests able to detect Omicron

The Roche subsidiary TIB Molbiol has developed new coronavirus testing kits that can also detect the new Omicron variant of...

Read More
1 2 3 31

Do you have a question? We'd like to hear from you.